Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 82 results:
Συντάκτης Τίτλος Τύπος [ Έτος(Asc)]
Φίλτρα: Συντάκτης is Pectasides, Dimitrios  [Clear All Filters]
2014
Purrington, K. S., Slager S., Eccles D., Yannoukakos D., Fasching P. A., Miron P., et al. (2014).  Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer.. Carcinogenesis. 35(5), 1012-9.
Vassilakopoulou, M., Togun T., Dafni U., Cheng H., Bordeaux J., Neumeister V. M., et al. (2014).  In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients.. PLoS One. 9(6), e99131.
2013
Pentheroudakis, G., Kotoula V., De Roock W., Kouvatseas G., Papakostas P., Makatsoris T., et al. (2013).  Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.. BMC Cancer. 13, 49.
Fountzilas, G., Dafni U., Bobos M., Kotoula V., Batistatou A., Xanthakis I., et al. (2013).  Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy.. BMC Cancer. 13, 163.
Fountzilas, E., Kotoula V., Angouridakis N., Karasmanis I., Wirtz R. M., Eleftheraki A. G., et al. (2013).  Identification and validation of a multigene predictor of recurrence in primary laryngeal cancer.. PLoS One. 8(8), e70429.
Fountzilas, G., Kotoula V., Pectasides D., Kouvatseas G., Timotheadou E., Bobos M., et al. (2013).  Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial.. PLoS One. 8(7), e69256.
Stavropoulou, A. V., Fostira F., Pertesi M., Tsitlaidou M., Voutsinas G. E., Triantafyllidou O., et al. (2013).  Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases.. PLoS One. 8(3), e58182.
Strimpakos, A., Pentheroudakis G., Kotoula V., De Roock W., Kouvatseas G., Papakostas P., et al. (2013).  The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab.. Clin Colorectal Cancer. 12(4), 267-274.e2.
Pentheroudakis, G., Kotoula V., Eleftheraki A. G., Tsolaki E., Wirtz R. M., Kalogeras K. T., et al. (2013).  Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG).. PLoS One. 8(7), e70634.
2012
Fountzilas, G., Dafni U., Bobos M., Batistatou A., Kotoula V., Trihia H., et al. (2012).  Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.. PLoS One. 7(6), e37946.
Pectasides, D., Papaxoinis G., Kotoula V., Fountzilas H., Korantzis I., Koutras A., et al. (2012).  Expression of angiogenic markers in the peripheral blood of docetaxel-treated advanced breast cancer patients: a Hellenic Cooperative Oncology Group (HeCOG) study.. Oncol Rep. 27(1), 216-24.
Korantzis, I., Kalogeras K. T., Papaxoinis G., Kotoula V., Koutras A., Soupos N., et al. (2012).  Expression of angiogenic markers in the peripheral blood of patients with advanced breast cancer treated with weekly docetaxel.. Anticancer Res. 32(10), 4569-80.
Kotoula, V., Krikelis D., Karavasilis V., Koletsa T., Eleftheraki A. G., Televantou D., et al. (2012).  Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS).. BMC Cancer. 12, 342.
Fountzilas, G., Valavanis C., Kotoula V., Eleftheraki A. G., Kalogeras K. T., Tzaida O., et al. (2012).  HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.. J Transl Med. 10, 10.
Razis, E., Kalogeras K. T., Kotoula V., Eleftheraki A. G., Nikitas N., Kronenwett R., et al. (2012).  Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.. Clin Breast Cancer. 12(3), 183-93.
Gogas, H., Dafni U., Karina M., Papadimitriou C., Batistatou A., Bobos M., et al. (2012).  Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial.. Breast Cancer Res Treat. 132(2), 609-19.
Fostira, F., Tsitlaidou M., Papadimitriou C., Pertesi M., Timotheadou E., Stavropoulou A. V., et al. (2012).  Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study.. Breast Cancer Res Treat. 134(1), 353-62.
Kosmidis, P. A., Syrigos K., Kalofonos H. P., Dimopoulos M-A., Skarlos D., Pavlidis N., et al. (2012).  Vinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2.. Anticancer Res. 32(1), 175-81.
Pectasides, D., Papaxoinis G., Kalogeras K. T., Eleftheraki A. G., Xanthakis I., Makatsoris T., et al. (2012).  XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis.. BMC Cancer. 12, 271.
2011
Stevens, K. N., Vachon C. M., Lee A. M., Slager S., Lesnick T., Olswold C., et al. (2011).  Common breast cancer susceptibility loci are associated with triple-negative breast cancer.. Cancer Res. 71(19), 6240-9.
Haiman, C. A., Chen G. K., Vachon C. M., Canzian F., Dunning A., Millikan R. C., et al. (2011).  A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer.. Nat Genet. 43(12), 1210-4.
Fountzilas, G., Kourea H. P., Bobos M., Televantou D., Kotoula V., Papadimitriou C., et al. (2011).  Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation.. Anticancer Res. 31(9), 3007-18.
Pentheroudakis, G., Batistatou A., Kalogeras K. T., Kronenwett R., Wirtz R. M., Bournakis E., et al. (2011).  Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study.. Breast Cancer Res Treat. 127(1), 179-93.
Papadimitriou, C. A., Papakostas P., Karina M., Malettou L., Dimopoulos M. A., Pentheroudakis G., et al. (2011).  A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study.. BMC Med. 9, 10.
2010
Kalofonos, H. P., Papakostas P., Makatsoris T., Papamichael D., Vourli G., Xanthakis I., et al. (2010).  Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer.. Anticancer Res. 30(10), 4325-33.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές